CN100339075C - 使用链烷醇胺处理头发和指甲 - Google Patents
使用链烷醇胺处理头发和指甲 Download PDFInfo
- Publication number
- CN100339075C CN100339075C CNB038148536A CN03814853A CN100339075C CN 100339075 C CN100339075 C CN 100339075C CN B038148536 A CNB038148536 A CN B038148536A CN 03814853 A CN03814853 A CN 03814853A CN 100339075 C CN100339075 C CN 100339075C
- Authority
- CN
- China
- Prior art keywords
- hair
- acid
- alkanolamine
- described method
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 59
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 76
- 210000004905 finger nail Anatomy 0.000 claims abstract description 45
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 25
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 22
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 21
- -1 fatty acid ester Chemical class 0.000 claims abstract description 20
- 235000019152 folic acid Nutrition 0.000 claims abstract description 14
- 239000011724 folic acid Substances 0.000 claims abstract description 14
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 13
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960002887 deanol Drugs 0.000 claims abstract description 13
- 229960000304 folic acid Drugs 0.000 claims abstract description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 9
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 9
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 21
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 8
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims description 8
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- XGIKILRODBEJIL-UHFFFAOYSA-N 1-(ethylamino)ethanol Chemical group CCNC(C)O XGIKILRODBEJIL-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 229910000077 silane Inorganic materials 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 claims description 3
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- 229940102253 isopropanolamine Drugs 0.000 claims description 3
- 229960004418 trolamine Drugs 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 229960004592 isopropanol Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 210000000282 nail Anatomy 0.000 abstract description 18
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 239000011159 matrix material Substances 0.000 abstract description 10
- 102000011782 Keratins Human genes 0.000 abstract description 9
- 108010076876 Keratins Proteins 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 9
- 229930195729 fatty acid Natural products 0.000 abstract description 9
- 239000000194 fatty acid Substances 0.000 abstract description 9
- 235000002374 tyrosine Nutrition 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000000699 topical effect Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 210000004906 toe nail Anatomy 0.000 abstract description 3
- 229960004441 tyrosine Drugs 0.000 abstract description 3
- 230000003779 hair growth Effects 0.000 abstract description 2
- 230000036562 nail growth Effects 0.000 abstract description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 abstract 1
- 239000002932 luster Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 22
- 241001597008 Nomeidae Species 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 4
- 239000004261 Ascorbyl stearate Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000019276 ascorbyl stearate Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000005482 chemotactic factor Substances 0.000 description 3
- 210000000589 cicatrix Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000000598 lipoate effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LPJXPACOXRZCCP-VIFPVBQESA-N (2s)-2-benzamidopentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 LPJXPACOXRZCCP-VIFPVBQESA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- MUZIZEZCKKMZRT-UHFFFAOYSA-N 1,2-dithiolane Chemical compound C1CSSC1 MUZIZEZCKKMZRT-UHFFFAOYSA-N 0.000 description 1
- SQNSGVROVCQNIM-UHFFFAOYSA-N 1-(ethylamino)-1-(methylamino)ethanol Chemical compound C(C)NC(C)(O)NC SQNSGVROVCQNIM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- YGXKWXGMWPKPQK-UHFFFAOYSA-N 5-(dithiolan-4-yl)pentanoic acid Chemical compound OC(=O)CCCCC1CSSC1 YGXKWXGMWPKPQK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010017707 Fibronectin Receptors Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000003741 hair volume Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- FUMFVZQFUSTSBW-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-5-(dithiolan-3-yl)pentanamide Chemical compound CN(C)CCNC(=O)CCCCC1CCSS1 FUMFVZQFUSTSBW-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
- 208000012313 wound discharge Diseases 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
局部施用包含链烷醇胺如二甲氨基乙醇的组合物增加头发和指甲的光滑和表面均匀性并促进头发和指甲生长。施加到头发、含毛球的下部皮肤、手指甲或脚趾甲，以及含指甲基质的甲旁区域增加弹性并提高头发和指甲的光泽，软化其角蛋白基质，抑制发炎从而促进上部角蛋白的形成。在大多数实施方式中，链烷醇胺组合物包含至少一种其它的辅助成分如酪氨酸、硫辛酸、叶酸、α-羟基酸，或抗坏血酸的脂肪酸酯以增强处理的有益效果。
Description
相关申请的交叉引用
本申请要求2002年6月26日提交的美国专利申请No.10/180,412的优先权。
技术领域
本发明涉及用于改进头发和指甲的健康和外观，软化头发和指甲中的角蛋白，以及由通过毛球(hair bulb)和指甲基质生成更均匀角蛋白的组合物和方法。
背景技术
从许多对指甲和头发的处理及秃顶治疗的远古的描述中显然看到，数千年来，拥有并保持健康外观的头发和指甲的愿望对人类十分重要。在当代，巨大的产业正致力于使我们所拥有的头发量、发辫的质量和指甲的美化处理达到最优化。
每根头发都是从皮肤中的毛囊(follicle)中生长出来的，通常与皮肤表面成一定角度。在头发的底部是毛球，事实上头发是从中长出的。在毛囊中有皮脂腺(其产生润滑头发和皮肤的(皮脂)油)、立毛肌(erector pili muscle)和供给头发营养的毛细管。实际的发杆(shaft)从毛球中心部分内的活性细胞生长出来。毛鞘(sheath)和所包含的毛发从毛球中长出并形成硬质角蛋白的同心圆筒层结构的头发，高度不可溶的纤维硬蛋白质也是指甲的主要成分。
指甲生长如同从在手指和脚趾末端背面上的表皮下的指甲基质中挤出一般。由于手指甲和脚趾甲，特别是手指甲不断与环境接触，它们容易受到大量的小损伤，有时是较大的损伤。角蛋白的坚韧性质使得很难处理损伤的头发和易脆的指甲。因此希望有新的和改进的处理头发和指甲的方法，以使其更光滑、更柔软、更有光泽和弹性，以及更健康的外观。
发明内容
本发明的主要目的是提供一种能局部使用以改善头发和指甲外观使其更均匀和更光滑的组合物。本发明更具体的目的是赋予头发和指甲的角蛋白基质柔软性，并通过毛球和指甲基质提供上部角蛋白的形成，以促进头发生长优良及指甲板更好。
本发明实现了这些目的和其它目的，本发明提供包含链烷醇胺如乙氨基乙醇、甲氨基乙醇、二甲氨基乙醇、异丙醇胺、三乙醇胺、异丙醇二甲基胺、乙基乙醇胺、2-丁醇胺、胆碱、丝氨酸，及其混合物的局部组合物(topicalcomposition)，该组合物施加到头发和下部皮肤区域，即包含发根和发球的皮肤如头皮，以及施加到指甲和指甲的甲旁区域，特别是指甲板基质上面的皮肤，以使头发和指甲更均匀和更光滑，以刺激更均匀角蛋白的生产并治疗发球和指甲基质内的及周围的亚临床和临床炎症。特别优选为二甲氨基乙醇。活性链烷醇胺成分的量为组合物总重量的约0.1-10％，更窄范围为1-3％。辅助成分如酪氨酸、硫辛酸、叶酸、抗坏血酸的脂肪酸酯如棕榈酸抗坏血酸酯，和/或α-羟基酸如羟基乙酸可添加到本发明的配方中。处理过的头发变得更柔软、更光亮和更易于打理，以及指甲变得脆性较小和更有光泽。从而获得了显著的美容效益。
具体实施方式
本发明基于一项发现，即在将链烷醇胺提供给周围皮肤区域的同时，将链烷醇胺施加到头发和指甲上对角蛋白的影响与使用胶原蛋白所观察到的相同，即局部链烷醇胺处理的有益效果。
以前已经提出将链烷醇胺组合物用于皮肤疤痕的治疗(Perricon的美国专利No.6,319,942；在此引入该专利及其后引用的文献的全部内容作为参考)。伤口愈合后发生在三个独立阶段：发炎、形成颗粒组织、形成基质中，而伤口愈合会产生疤痕。(其综述参见Sahl，W.J.，and Clever，H.，Internat.J.Derm.，1994，33：681-691(part I)and 763-769(part II))。不受任何理论束缚，链烷醇胺在所有这三个阶段中看起来有利于疤痕治疗，特别是对肥大的和瘢痕瘤疤痕的治疗。在第一阶段，内皮细胞、补偿和伤口处的血小板的破坏释放趋化因子(chemotactic factor)，这有助于消除感染和外来碎屑，趋化因子导致中性白细胞、淋巴细胞和巨噬细胞的注入。在所有的发炎过程中会产生自由基，为下一阶段安置支架结构(scaffold)，该自由基破坏细胞膜并导致形成氧化蛋白质和脂肪及交联的新胶原蛋白。
在发炎阶段的结束时，随着内皮细胞和纤维原细胞的流至伤口开始了粒化阶段。在该阶段另外的关键细胞是巨噬细胞和血小板。通过释放血小板衍生生长因子(PDGF)、肿瘤坏死生长因子(TGF)-α，和表皮生长因子类似的物质，巨噬细胞促使开始粒化。活性血小板释放表皮生长因子(EGF)、PDGF、TGF-α和TGF-β。这些物质在上皮再形成(re-epithelialization)过程中一起发挥作用，其中在临时基质上的角质形成细胞迁入毛鞘中，和产生它们本身的纤连蛋白受体，该临时基质主要由纤维蛋白、纤连蛋白、V型胶原、韧粘素(tenascin)组成。
一旦出现上皮再形成，角质形成细胞重新开始它们通常的分化形式，并且开始基质形成。基质形成主要由由纤维原细胞调节的真皮基质的构造而组成。纤维原细胞的趋化性导致产生大量的透明质酸酯、纤连蛋白、I型和III型胶原蛋白。在伤口修复阶段的早期这些成分包含临时细胞外基质的大部分。在胶原蛋白/纤连蛋白的支架结构中，透明质酸(HA)生成开放波纹图案(open-weave pattern)，使纤维原细胞容易移动。在伤口愈合约第五天之后，HA的生成量下降，并且在硫酸软骨素B(dermatan sulfate)中的硫酸软骨素(chronroitin sulfate)的含量增加。纤连蛋白沉淀在胶原蛋白中并开始收缩伤口。在生化收缩阶段期间，观察到存在有透明质酸酶和蛋白酶，促进了I型胶原蛋白的合成，并提高了硫酸软骨素、硫酸软骨素B和蛋白聚糖的水平。这些物质在一起重新构建了该基质。在愈合过程的结束时，最终疤痕显示出主要与表皮平行的胶原蛋白纤维。
再次，不受任何理论束缚，链烷醇胺在发囊和指甲基质中，及对角蛋白本身都发挥了类似的效应。主要是由于角蛋白中羰基的形成，发杆趋向于变得暗淡、脆弱和粗糙。类似地，指甲板也变得干燥和易裂。链烷醇胺是天然的渗透剂(penetrant)，同时在角蛋白基质内起着抗氧化剂和润滑剂的作用，从而使得头发和指甲更柔软、更光亮、更平滑和更有弹性。同时，链烷醇胺渗透至头皮和包含毛球的其它皮肤区域，以及指甲的甲旁区域，以促进更平滑和上部角蛋白的形成。由于一直暴露在环境中，以及有时由于切伤和擦伤、感染、皮炎、脂溢性皮炎等而处于更极端的病理条件下，头发和指甲不断地受到物理和化学的损伤，大部分人在毛球和指甲板的真皮基质的内部或周围若无临床发炎也会有亚临床发炎。该发炎导致形成欠理想的角蛋白构造。链烷醇胺是促进发杆更良好的生长和更好的指甲板形成的天然消炎剂。
在本发明的实施中，将包含有效量的下式的链烷醇胺的组合物局部施加到头发或指甲以使它们更均匀和更光滑，以及施加到周围的皮肤区域以抑制毛球和指甲基质区域内发炎，其中链烷醇胺为：
其中X、Y和Z选自氢、C1-C3烷基、C2-C4烷醇基，其中X、Y和Z中至少一个是带至少一个羟基和任选至少一个羧基的C2-C4烷醇基。在此处所用的术语“指甲”包括手指甲或脚趾甲，或者两者。对本发明有用的化合物包括但不限定为乙氨基乙醇、甲氨基乙醇、二甲氨基乙醇、异丙醇胺、三乙醇胺、异丙醇二甲基胺、乙基乙醇胺、2-丁醇胺、胆碱、丝氨酸，及其混合物。许多优选的实施方式采用甲氨基氨基乙醇、二甲氨基乙醇、乙氨基乙醇，和/或三乙醇胺；特别优选为二甲氨基乙醇(DMAE)。
处理头发和指甲所需的链烷醇胺的量本质上不固定，需要取决于所用的链烷醇胺的性质，所用的其它活性和辅助成分的数量和类型，使用者的头发和指甲的类型，以及处理条件的严重性和程度。本发明的大部分组合物包含占组合物总重量约0.1％至约10％重量的，更窄为约0.25％至约5-7％重量的，且在许多情况下为约1％至约3％重量的链烷醇胺如二甲氨基乙醇，通常与下面充分描述的皮肤病学上可接受的载体一起使用。在下列的一些实施例中，用于说明本发明的有效组合物包含约2％至约3％的DMAE。
本发明的许多链烷醇胺组合物包含至少一种辅助成分，该辅助成分包括但不限定为酪氨酸、硫辛酸、叶酸、α-羟基酸、抗坏血酸的脂肪酸酯，及维生素A和维生素A衍生物。许多实施方式采用一种以上的辅助成分。使用时，由于不同的作用机制，辅助成分若无协同效应(synergistic effects)仍具有附加效应。
本发明的包含酪氨酸的链烷醇胺组合物通常配制为含有占组合物总重量约0.01％至约6％，更窄为约0.03％至约5％，且在许多实施方式中为约0.2％至约3％重量的酪氨酸。在下列实施例中所说明的组合物含0.1-5％的酪氨酸。
在许多实施方式中硫辛酸是辅助成分。术语“硫辛酸”包括硫辛酸(1，2-二硫戊环(dithiolane)-3-戊酸、1，2-二硫戊环-4-戊酸)、C8H14O2S2，分子量为206.32，及其还原形式：二氢硫辛酸。它以不同的名称被称为醋酸替代因子(acetate replacing factor)、硫辛酸A和丙酮酸酯氧化因子。如上所述，为方便起见，在此使用的硫辛酸包括硫辛酸及其衍生物，其中在本发明的实施中讨论了作为辅助成分的“硫辛酸”(或lipoic acid，LA)的性质和优点。
“硫辛酸衍生物”包括硫辛酸酯，特别是烷基酯如脂肪酸酯；酰胺，特别是那些从天然形成的硫辛酰胺分离或仿制的酰胺；盐，特别是碱金属盐；酐，以及具体包括其还原形式，二氢硫辛酸及其酯、酰胺和盐。一种特别有效的衍生物是Sen，C.K.等描述(Free Radical Biol.Med.，1998，25：89)的N，N-二甲基-2-酰胺乙基硫辛酸酯(N，N-dimethyl，N-2-arnidoethyl lipoate)并称为硫辛酸加(LA-Plus)，其显示出被增强的细胞摄入和生物活性，在本发明的实施中非常有用。由于硫辛酸既是脂肪可溶的又是水溶的，因此本发明的优点是其可以用于脂基或水基组合物中，并且容易渗透。衍生物还包括那些含有本领域的技术人员公知的其它活性基团的物质。正如在此使用的，术语“衍生物”包括硫辛酸的代谢前体。使用硫辛酸衍生物时，它们必须为硫辛酸的功能等价物。本发明的其它优点还在于硫辛酸具有有益于对皮肤损伤，特别是发炎和老化(Perricone的美国专利No.5,709,868)的处理，以及对疤痕，特别对肥大的和瘢痕瘤疤痕(Perricone的美国专利No.5,965,618)的处理的性质。在一些典型的实施方式中，该组合物包含约0.1％至约7重量％，更窄为0.25％至约5重量％的硫辛酸。在一实施方式中采用了约2％至约5％的硫辛酸。
在许多实施方式中α-羟基酸是辅助成分，单独或与酪氨酸和硫辛酸，以及下面描述的那些物质一起使用。正如在此使用的，术语“α-羟基酸”是指并包括含至少一个羟基和至少一个羧基，且其中至少一个羟基在α-碳原子上的总体类型的有机化合物。通常该化合物是在α-碳原子上具有至少一个羟基和至少一个羧基的有机酸，并可含有包括另外的羟基和羧基部分的其它官能团。优选的α-羟基酸和/或α-羟基酸衍生物的结构体积不大，这样其能很好地渗入皮肤，因此采用具有1至3个碳原子骨架，如Perricone的美国专利No.5,965,618的第六列4至29行中详细描述的那些化合物。使用时，优选为乙醇酸和/或乳酸或它们的衍生物。乙醇酸特别有效。乙醇酸或其它α-羟基酸通常存在的量占总的组合物的约1％至约10％，更窄为约3％至约7％。
在其它实施方式中，采用脂溶性的抗坏血酸(vitamin C)的脂肪酸酯作为辅助成分，其单独或与酪氨酸、硫辛酸和/或α-羟基酸和下述的叶酸一起使用。优选抗氧化性更强的抗坏血酸的饱和脂肪酸酯，包括但不限定为月桂酸抗坏血酸酯、豆蔻酸抗坏血酸酯、棕榈酸抗坏血酸酯、硬脂酸抗坏血酸酯和山萮酸抗坏血酸酯。正如技术人员所知的，抗坏血酸的酯化物包括一酯、二酯、三酯、四酯，及其混合物。在一实施方式中采用棕榈酸抗坏血酸酯。如该处所指的，在描述脂肪酸酯(如硬脂酸抗坏血酸酯)描述时，包括具有以该酯为主(如以硬脂酸酯为主)的组合物。采用氢化油或脂肪或其一部分可以制备该酯，该酯含有少量的其它酯。例如采用低芥酸菜子油制备硬脂酸抗坏血酸酯，通常包含约4％的棕榈酸抗坏血酸酯。采用硬脂酸抗坏血酸酯作为辅助成分是本发明的优点，它们帮助稳定组合物中的链烷醇胺。棕榈酸抗坏血酸酯等抗坏血酸的酯化物通常存在的量占组合物总重量的约0.5％至约15％，优选为约1％至约7-10％。维生素A或维生素A的衍生物以相似的浓度作为任选或附加的组分。维生素A或维生素A的衍生物包括但不限定为视黄醇、棕榈酸视黄酯、视黄酸、视黄醛和丙酸视黄酯。
在一些组合物中有用的另一辅助成分是叶酸。“叶酸”指N-[4-[[(2-氨基-1，4-二氢-4-氧-6-蝶啶基)甲基]氨基]苯甲酰基]-谷氨酸，有时也称为蝶酰基谷氨酸、N-p-[[(2-氨基-4-羟基-6-蝶啶基)甲基]氨基]苯甲酰基]-谷氨酸或N-p-[[(2-氨基-4-羟基嘧啶并[4，5-b]吡嗪-6-基)甲基氨基]苯甲酰基-谷氨酸。可以使用叶酸的生理盐如钾盐或钠盐和简单的C1至C4酯，条件是其能显示叶酸的生理学性质。如此处所用，当使用术语“叶酸”时，其包含生物学上等价的衍生物。通常的叶酸或叶酸酯的浓度为约0.025％至约1％重量，更窄些为约0.05％至约0.5％重量。
当单独使用或与其它成分一起使用时，仅需要有效量的链烷醇胺组合物，以获得可观察到的头发和指甲的改善，因此通常与载体，特别是其中链烷醇胺活性成分本质上是可溶的或使其有效增溶(例如成为乳液或微乳液)的载体一起局部施用就可达到效果。当使用时，在不使活性成分氧化或失活的意义上，以及在不对其施用的皮肤区域产生任何不利效应的意义上，载体是惰性的。在本发明的优选实施中，将该有效成分和皮肤病学上可接受的载体或媒介(如作为洗液、乳剂、膏剂、肥皂、棒体等)混合在一起施用以方便使用，而且在一些情况中，例如通过将其施加到用于毛球和甲旁的指甲区域治疗的附近的皮肤区域，还可能带来的另外的治疗效果。当用于皮肤病的组合物的载体由相对单一的溶剂或分散剂如水组成时，通常优选载体包含更有益于局部施用的组合物，特别是会在其施用的头发或指甲上形成膜或层的组合物，这样使组合物的施用局部化，并阻止其在浸入水中后被洗去和/或有助于其渗入。许多制剂为本领域公知，包括洗液，该洗液就含有油和/或醇和润滑剂蔬菜油、烃油和蜡、硅油、动物或海产物的脂肪和油、甘油酯衍生物、脂肪酸或脂肪酸酯或醇或醇酯、卵磷脂、羊毛脂和衍生物、多羟基醇或酯、蜡酯、固醇、磷酯等。尽管有些润滑剂本身具有乳化性质，但该制剂通常也包括乳化剂(非离子的、阳离子的和阴离子的)。通过利用不同比例的成分和/或通过包含增稠剂(thickening agents)如胶或亲水胶体的其它形式可以将这些相同的一般的成分配制成非洗液的乳剂，或者凝胶，或指甲涂剂。一种优选的实施方式是清洗剂，另一种是洗发精，以及另外的为洗液、乳剂和凝胶。该组合物在此指皮肤上或皮肤病学上可接受的载体，并采用本领域公知的常规技术配制。尽管链烷醇胺和辅助成分可以配制成洗发精，但对头发的优选施用是头发整饰剂(rinse)。对指甲的优选使用指尖浸泡剂(fingertip soak)，但组合物可以作为洗液、乳剂或药膏来喷涂或涂布。
由其对活性组分的溶解或分散能力而选择的合适的载体包括水、乙醇、油等。通常，取决于施用方法及所用的有效和辅助成分，载体中即使低浓度的活性成分也是合适的。温和的皮肤和头发的条件一般比敏锐条件要求较低浓度的活性成分。然而，事实上，为了防止需反复施用，要求将局部施用的组合物配制为含有上面设定量的有效成分。通常在本发明方法的实施中，将组合物施加至洗过的头发和修剪过的指甲，情形一般为随着每次连续使用会观察到头发和指甲在逐渐改善。目前的临床研究已经确定没有遇到不良副反应。本发明的优点是不需要药学配方。
本发明的局部组合物可以包含在皮肤和头发护理组合物中常见的附加成分，例如着色剂、润滑剂、皮肤调理剂、乳化剂、保湿剂、防腐剂、香料、螯合剂等，条件是其与组合物的其它成分物理上和化学上相容。防腐剂包括但不限定为C1-C3烷基对羟基苯甲酸酯和苯氧基乙醇，通常其存在的量占组合物总重量百分比的约0.5％至约2.0％。润滑剂通常存在的量占组合物总重量的约0.01％至约5％，其包括但不限定为脂肪酯、脂肪醇、矿物油、聚醚硅氧烷共聚物，及其混合物。保湿剂通常存在的量占组合物总重量的约0.1％至约5％，其包括但不限定为多羟基醇如丙三醇，聚亚烷基二醇(如丁二醇、丙二醇、双丙甘醇、聚丙二醇和聚乙二醇)及其衍生物，亚烷基多醇及其衍生物，山梨醇、羟基山梨醇、己二醇、1，3-二丁醇、1，2，6-己三醇、乙氧基化甘油、丙氧基化甘油、及其混合物。乳化剂通常存在的量占组合物总重量的约1％至约10％，其包括但不限定为硬脂酸、十六醇、硬脂醇醚(steareth)2、硬脂醇醚20、丙烯酸酯/丙烯酸C10-30烷基酯交联聚合物(crosspolymer)，及其混合物。螯合剂通常存在的量占组合物总重量的约0.01％至约2％，其包括但不限定为乙二胺四醋酸(EDTA)及其衍生物和盐，二羟基乙基氨基乙酸，及其混合物。抗氧化剂通常存在的量占组合物总重量的约1％至约10％，其包括但不限定为丁基化羟基甲苯(BHT)；维生素C和/或维生素C衍生物，如抗坏血酸的脂肪酸酯，特别是棕榈酸抗坏血酸酯；丁基化羟基苯甲醚(BHA)；苯基-α-萘胺；对苯二酚；没食子酸丙酯；去甲二氢愈创木酸；维生素E和/或维生素E的衍生物，包括tocotrienol和/或tocotrienol衍生物；泛酸钙；绿茶提取物；混合的聚苯酚，及这些物质的混合物。如上所述，特别优选的抗氧化剂是给头发提供其它益处的那些物质，如棕榈酸抗坏血酸酯(参见Perricone的美国专利Nos.4,775,530、5,376,361、5,409,693、5,545,398、5,574,063、5,643,586、5,709,868、5,879,690、5,965,618、5,968,618、6,051,244、6,162,419和6,191,121中的附加组分和方法)
在许多组合物中应用缓冲剂。优选缓冲剂的量为使得组合物的pH值为约4.5至约8.5，更优选为约5.5至约8.5，最优选为约6.5至约8.0。通常的缓冲剂是在化妆品中普通可见的化学和物理稳定的试剂，并可包括也是辅助成分的化合物如柠檬酸、苹果酸和乙醇酸。
在试验研究中，头发整饰剂配制成在磷脂基、阳离子头发调理剂或非离子洗发精中含0.1％至约3％的DMAE，在对全部头发的易打理、柔软和光亮方面的非限制性和非盲性(unblinded)比较中，该头发整饰剂比不含有效成分的相同的头发护理产品性能超出。该效果对于太阳和氯气漂白的受验者更加明显。
将受验者一支手的指端浸入在磷脂基中含3％DMAE和5％酪氨酸的溶液中该手的手指甲比仅浸入磷脂基的另一支手的手指甲的脆性更小且更平整。当将该溶液局部施加或用刷子涂布至指甲时可以观察到相同的效果。
本发明的优点是采用链烷醇胺组合物得到了大量的总结如上的有益效果：链烷醇胺有益于抑制发炎，治疗和防止皮肤受到损害和老化(Perricone的美国专利No.5,554,647)，增加皮下肌肉张力(tone)(同前)，防止和治疗痤疮疤痕和其它缺陷，并使皮肤毛孔明显收缩，使得头发处理期间用组合物浸透的区域、头皮、指甲周围的甲旁区域的皮肤外观更清爽、更平滑，并刺激发杆生长更好，指甲板更平滑、更强硬。有益效果是即时的，而结果是累积的，本发明的配方能被皮肤和头皮很好地接受。随着连续使用，头发、指甲，及其周围皮肤都得到改善。已经讨论的本发明的另一个重要的优点是链烷醇胺是消炎剂，能治疗脂溢性皮炎和各种皮肤病，减少手和头皮有受伤部分的人的受损伤和损伤周围区域中的红斑，和治疗对头发和指甲中通常的角蛋白的形成有不利作用的亚临床发炎。一起考虑时，所有这些效果增加了头发、指甲，及其周围皮肤的平滑和表面均匀性。
用本发明的组合物(通常用作洗发精和头发整饰剂)处理头发，使得头发更柔软、更易于打理和光亮，该效果在太阳或化学漂白包括氯气漂白的头发的处理中，特别是在进行充分长的时间处理以促进发杆更好生长之后表现明显。个别处理的头发的放大明显显示出比未处理者角蛋白更完好，更平滑，以及末端分叉较少。链烷醇胺组合物应用到指甲使得其变得更有光泽，并且脆性和凹痕减少。指甲板的放大显示出带很少凹坑的更好的薄层图案。如上总结，当不受任何理论束缚，优选的包含脂质渗透剂的组合物似乎将活性成分驱入发杆和指甲表面，软化角蛋白基质，给角蛋白提供柔软性并使其更有弹性，并同时促进在发囊和指甲基质中更好地产生角蛋白。而且，如同所述，该效果是累积的。连续使用增加了头发和指甲的外观。
上面的描述是为了教导本领域的技术人员如何实施本发明，没有打算将其所有明显的改进和变化进行详细描述，这些改进和变化对于阅读了该发明描述的技术人员是显而易见的。然而，其意指所有这些明显的改进和变化都包含在由下列的权利要求书所限定的本发明的范围内。该权利要求书旨在包含对满足本发明意指的目的有效的任何次序中所要求的成分和步骤，除非文中特别指出了反面。
Claims (12)
1.一种用于处理头发或指甲使其更均匀更光滑的方法，所述方法是用于非治疗目的的，所述方法包括向头发或指甲局部施加含有有效量的下式链烷醇胺的组合物，
其中，X、Y和Z选自氢、C1-C3烷基和C2-C4烷醇基，其中X、Y和Z中至少一个是带至少一个羟基和任选至少一个羧基的C2-C4烷醇基。
2.权利要求1所述的方法，其中所述链烷醇胺选自乙氨基乙醇、甲氨基乙醇、二甲氨基乙醇、异丙醇胺、三乙醇胺、异丙醇二甲基胺、乙基乙醇胺、2-丁醇胺、胆碱、丝氨酸，及其混合物。
3.权利要求2所述的方法，其中所述链烷醇胺是二甲氨基乙醇。
4.权利要求2所述的方法，其中所述组合物包含0.1％至10％重量的链烷醇胺。
5.权利要求4所述的方法，其中所述组合物包含1％至5％重量的链烷醇胺。
6.权利要求5所述的方法，其中所述组合物包含2％至3％重量的链烷醇胺。
7.权利要求1所述的方法，其中所述组合物包含至少一种选自硫辛酸、酪氨酸、α-羟基酸、叶酸、抗坏血酸脂肪酸酯，及其任何混合物的辅助成分。
8.权利要求7所述的方法，其中所述组合物包含作为辅助成分的0.01％至6％的酪氨酸。
9.权利要求7所述的方法，其中所述组合物包含作为辅助成分的0.1％至7％重量的硫辛酸。
10.权利要求7所述的方法，其中所述组合物包含0.025％至1％重量的叶酸。
11.权利要求7所述的方法，其中所述组合物包含1％至10％重量的乙醇酸。
12.权利要求7所述的方法，其中所述组合物包含0.5％至15％重量的棕榈酸抗坏血酸酯。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/180,412 | 2002-06-26 | ||
| US10/180,412 US6908941B2 (en) | 2002-06-06 | 2002-06-26 | Hair and nail treatments using alkanolamines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1662233A CN1662233A (zh) | 2005-08-31 |
| CN100339075C true CN100339075C (zh) | 2007-09-26 |
Family
ID=29999162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038148536A Expired - Fee Related CN100339075C (zh) | 2002-06-26 | 2003-06-26 | 使用链烷醇胺处理头发和指甲 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6908941B2 (zh) |
| EP (1) | EP1515715A4 (zh) |
| JP (1) | JP2005535640A (zh) |
| KR (1) | KR100681480B1 (zh) |
| CN (1) | CN100339075C (zh) |
| AU (1) | AU2003256301B2 (zh) |
| BR (1) | BR0312032A (zh) |
| CA (1) | CA2482745A1 (zh) |
| HK (1) | HK1077502A1 (zh) |
| IL (1) | IL164492A0 (zh) |
| MX (1) | MXPA04012527A (zh) |
| WO (1) | WO2004002411A2 (zh) |
| ZA (1) | ZA200408614B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005342A1 (en) * | 2002-02-07 | 2004-01-08 | Societe L'oreal S.A. | Topical administration of ascorbic acid to reinforce the cohesion of the dermo-epidermal junction |
| EP1651237B1 (en) * | 2003-08-04 | 2012-09-19 | Johnson & Johnson Consumer Companies, Inc. | Methods for treatment of dermatological conditions |
| KR100645090B1 (ko) * | 2005-01-13 | 2006-11-23 | (주)트리코진 | 비타민 ｃ 및 그 유도체를 포함하는 탈모 치료제 조성물 |
| US20090191138A1 (en) * | 2008-01-30 | 2009-07-30 | Mediquest Therapeutics, Inc. | Novel topical formulations for improving the appearance of nails |
| EP2196191A1 (fr) * | 2008-12-11 | 2010-06-16 | L'oreal | Composition cosmetique comprenant un compose heterocyclique disulfure et un agent reducteur et procede pour la deformation permanente des fibres keratiniques |
| US8465731B2 (en) * | 2010-03-12 | 2013-06-18 | Elc Management, Llc | Probiotic color cosmetic compositions and methods |
| US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
| MX2017013983A (es) | 2015-05-01 | 2018-03-15 | Oreal | Uso de agentes activos durante tratamientos quimicos. |
| BR112018010341B1 (pt) | 2015-11-24 | 2021-08-10 | L'oreal | Método para alteração da cor de cabelo |
| JP6930994B2 (ja) | 2015-11-24 | 2021-09-01 | ロレアル | 毛髪をトリートメントするための組成物 |
| US9974725B1 (en) | 2017-05-24 | 2018-05-22 | L'oreal | Methods for treating chemically relaxed hair |
| WO2019133785A1 (en) | 2017-12-29 | 2019-07-04 | L'oreal | Compositions for altering the color of hair |
| US11090249B2 (en) | 2018-10-31 | 2021-08-17 | L'oreal | Hair treatment compositions, methods, and kits for treating hair |
| US11419809B2 (en) | 2019-06-27 | 2022-08-23 | L'oreal | Hair treatment compositions and methods for treating hair |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1064212A (zh) * | 1991-02-11 | 1992-09-09 | 宋明春 | 健肤霜及其制备方法 |
| US5709868A (en) * | 1995-09-20 | 1998-01-20 | Perricone; Nicholas V. | Lipoic acid in topical compositions |
| US5965618A (en) * | 1997-11-17 | 1999-10-12 | Perricone; Nicholas V. | Treatment of scar tissue using lipoic acid |
| CN1073408C (zh) * | 1997-01-30 | 2001-10-24 | 北京贝拉芦荟开发研究中心 | 以天然芦荟为主要原料的芦荟系列化妆品 |
| US6319942B1 (en) * | 2001-06-06 | 2001-11-20 | Nicholas V. Perricone | Topical scar treatments using alkanolamines |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4847076A (en) * | 1987-08-28 | 1989-07-11 | Sterling Drug Inc. | Method for enhancing the body of hair |
| DE3912477A1 (de) * | 1989-04-15 | 1990-10-18 | Mueller Robert Dr | Aeusserlich anzuwendendes praeparat und seine verwendung |
| US5554647A (en) * | 1989-10-12 | 1996-09-10 | Perricone; Nicholas V. | Method and compositions for treatment and/or prevention of skin damage and aging |
| DE4419783A1 (de) * | 1994-06-06 | 1995-12-07 | Asta Medica Ag | Haarkur-Pflege-Shampoo |
| US5523078A (en) * | 1995-02-03 | 1996-06-04 | Michael E. Baylin | Method of preparing and composition for treatment of hair and scalp |
| AU6301396A (en) * | 1995-06-26 | 1997-01-30 | Hans Schwarzkopf Gmbh | Hair care products with at least one conditioner |
| US5681554A (en) * | 1995-06-28 | 1997-10-28 | Cosmair, Inc. | Composition for treating hair and method for using the same |
| KR0182100B1 (ko) * | 1996-04-12 | 1999-05-01 | 황춘근 | 골프공의 딤플 배열구조 |
| JPH1081614A (ja) * | 1996-09-06 | 1998-03-31 | Kao Corp | 毛髪化粧料 |
| JP2005500278A (ja) * | 2001-06-06 | 2005-01-06 | ブイ ペリコン，ニコラス | アルカノールアミンを使用する局所治療 |
-
2002
- 2002-06-26 US US10/180,412 patent/US6908941B2/en not_active Expired - Lifetime
-
2003
- 2003-06-26 EP EP03762018A patent/EP1515715A4/en not_active Ceased
- 2003-06-26 CN CNB038148536A patent/CN100339075C/zh not_active Expired - Fee Related
- 2003-06-26 AU AU2003256301A patent/AU2003256301B2/en not_active Ceased
- 2003-06-26 BR BR0312032-5A patent/BR0312032A/pt not_active IP Right Cessation
- 2003-06-26 JP JP2004517789A patent/JP2005535640A/ja active Pending
- 2003-06-26 KR KR1020047020941A patent/KR100681480B1/ko not_active IP Right Cessation
- 2003-06-26 WO PCT/US2003/019946 patent/WO2004002411A2/en active IP Right Grant
- 2003-06-26 MX MXPA04012527A patent/MXPA04012527A/es active IP Right Grant
- 2003-06-26 CA CA002482745A patent/CA2482745A1/en not_active Abandoned
-
2004
- 2004-10-11 IL IL16449204A patent/IL164492A0/xx unknown
- 2004-10-25 ZA ZA200408614A patent/ZA200408614B/xx unknown
-
2005
- 2005-10-26 HK HK05109500A patent/HK1077502A1/xx not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1064212A (zh) * | 1991-02-11 | 1992-09-09 | 宋明春 | 健肤霜及其制备方法 |
| US5709868A (en) * | 1995-09-20 | 1998-01-20 | Perricone; Nicholas V. | Lipoic acid in topical compositions |
| CN1073408C (zh) * | 1997-01-30 | 2001-10-24 | 北京贝拉芦荟开发研究中心 | 以天然芦荟为主要原料的芦荟系列化妆品 |
| US5965618A (en) * | 1997-11-17 | 1999-10-12 | Perricone; Nicholas V. | Treatment of scar tissue using lipoic acid |
| US6319942B1 (en) * | 2001-06-06 | 2001-11-20 | Nicholas V. Perricone | Topical scar treatments using alkanolamines |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004002411A3 (en) | 2004-08-26 |
| EP1515715A4 (en) | 2006-06-14 |
| CN1662233A (zh) | 2005-08-31 |
| HK1077502A1 (en) | 2006-02-17 |
| BR0312032A (pt) | 2005-03-22 |
| KR100681480B1 (ko) | 2007-02-09 |
| MXPA04012527A (es) | 2005-06-08 |
| WO2004002411A2 (en) | 2004-01-08 |
| EP1515715A2 (en) | 2005-03-23 |
| ZA200408614B (en) | 2006-05-31 |
| IL164492A0 (en) | 2005-12-18 |
| KR20050022009A (ko) | 2005-03-07 |
| CA2482745A1 (en) | 2004-01-08 |
| AU2003256301A1 (en) | 2004-01-19 |
| US6908941B2 (en) | 2005-06-21 |
| JP2005535640A (ja) | 2005-11-24 |
| US20040081634A1 (en) | 2004-04-29 |
| AU2003256301B2 (en) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100339075C (zh) | 使用链烷醇胺处理头发和指甲 | |
| US6932963B2 (en) | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines | |
| WO2002015860A1 (en) | Topical antioxidant having vitamin c and method of combination with topical agent by user | |
| US20040185077A1 (en) | Treatment of acne using alkonolamine compositions | |
| FR2917969A1 (fr) | Utilisation cosmetique d'un derive d'acide imido-percarboxylique a titre d'agent desquamant | |
| CN1365662A (zh) | 用于减少眼睛下部黑眼圈出现的方法 | |
| EP1076549B1 (fr) | Utilisation d'inhibiteurs de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute | |
| FR2798855A1 (fr) | Utilisation de complexes inorganiques-organiques dans une composition a usage topique | |
| CN110882181B (zh) | 视黄醇油组合物 | |
| EP0858319B1 (fr) | Utilisation d'acides carboxyliques porteurs d'une fonction soufr e pour favoriser la desquamation de la peau ou stimuler le renouvellement epidermique | |
| CA2448596C (en) | Topical treatments using alkanolamines | |
| FR2903009A1 (fr) | Composition cosmetique et/ou dermatologique associant un derive de c-glycoside et un agent desquamant | |
| AU2014217909A1 (en) | Topical composition for stimulating epidermis and dermis layers of the skin | |
| US20030017177A1 (en) | Reduction of skin pore size using alkanolamines | |
| FR2912052A1 (fr) | Composition a base de derives d'acides salicylique | |
| AU2002312382A1 (en) | Topical treatments using alkanolamines | |
| FR2757058A1 (fr) | Compositions cosmetiques et/ou dermatologiques contenant du p-chlorophenoxyacetate de dimethylaminoethyle pour prevenir et reparer les alterations dermo-epidermiques et des phaneres | |
| RU2804367C2 (ru) | Композиция ретинолового масла | |
| US6169110B1 (en) | Rejuvenating the skin using a combination of vitamin A and alphahydroxy acids | |
| WO2015082856A1 (fr) | Combinaison d'un alcool et d'un composé issu d'acides gras | |
| WO2022269176A1 (fr) | Utilisation cosmetique d'un extrait de phacelie, notamment pour le soin des phaneres | |
| CA2686511A1 (fr) | Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations | |
| FR2821554A1 (fr) | Compositions topiques contenant au moins un derive d'ethanolamine pour le traitement ou la prevention des dommages de la peau associes au vieillissement de la peau et procedes comestique associes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1077502 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: N.V. PERRICONE LIMITED LIABILITY COMPANY Free format text: FORMER OWNER: PERRICONE NICHOLAS V. Effective date: 20071109 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20071109 Address after: American Connecticut Patentee after: N.V. Perricone LLC Address before: American Connecticut Patentee before: Perricone Nicholas V. |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1077502 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070926 |